You’ve probably never heard of NGLY1 deficiency.

It’s an ultra-rare genetic disorder with a patient population small enough to fit in a single room.

Children born with mutations in the NGLY1 gene can’t produce functional N-glycanase 1, an enzyme their cells need for basic protein quality control. Without it, they face progressive movement disorders, seizures, cognitive decline, and developmental regression.

There’s no approved treatment.

There’s never been one.

Grace Science, based in Menlo Park, California, has been developing GS-100, an AAV9-based gene replacement therapy designed to restore NGLY1 enzyme activity. It’s the first and only therapy in development for this indication.

Today, the FDA granted GS-100 RMAT designation (Regenerative Medicine Advanced Therapy), based on early clinical evidence from their ongoing Phase 1/2/3 trial.

Patients treated for at least 52 weeks showed improvements in motor function and cognitive abilities. No specific numbers have been disclosed, but in a disease with zero therapeutic options, directional improvement over a year is the kind of signal that gets the FDA’s attention.

RMAT designation isn’t ceremonial. The FDA created it for regenerative medicine therapies that treat serious or life-threatening conditions and show preliminary evidence of benefit. For Grace Science, it unlocks enhanced FDA engagement, the possibility of priority review, and a faster path to approval.

In diseases this rare, traditional clinical development is brutal. You can’t randomize 500 patients when there aren’t 500 patients. Endpoints that work for common diseases fall apart when your trial has single-digit enrollment. RMAT is the regulatory system bending to accommodate that reality.

Grace Science appears to have built their case on functional endpoints, measuring real changes in how patients move and think rather than biochemical surrogates. In a disease this small, those functional measures carry more weight with regulators.

The vector choice matters too.

AAV9 has good CNS penetration, which is critical for a disease that hits neurological function this hard. The gene replacement logic is straightforward: deliver a working copy of NGLY1 and let the cells do the rest.

AAV gene therapies have been accumulating quiet regulatory wins recently. GS-100 fits that pattern, with the added weight of being the only program for a disease that has nothing else.